Cargando…

Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients

BACKGROUND AND PURPOSE: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to d...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogura, Hiromu, Hatip-Al-Khatib, Izzettin, Suenaga, Midori, Hatip, Funda Bolukbasi, Mishima, Takayasu, Fujioka, Shinsuke, Ouma, Shinji, Matsunaga, Yoichi, Tsuboi, Yoshio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477135/
https://www.ncbi.nlm.nih.gov/pubmed/34611554
http://dx.doi.org/10.1016/j.ensci.2021.100369
_version_ 1784575781472567296
author Ogura, Hiromu
Hatip-Al-Khatib, Izzettin
Suenaga, Midori
Hatip, Funda Bolukbasi
Mishima, Takayasu
Fujioka, Shinsuke
Ouma, Shinji
Matsunaga, Yoichi
Tsuboi, Yoshio
author_facet Ogura, Hiromu
Hatip-Al-Khatib, Izzettin
Suenaga, Midori
Hatip, Funda Bolukbasi
Mishima, Takayasu
Fujioka, Shinsuke
Ouma, Shinji
Matsunaga, Yoichi
Tsuboi, Yoshio
author_sort Ogura, Hiromu
collection PubMed
description BACKGROUND AND PURPOSE: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. METHODS: A total of 107 subjects were included in this study, divided into three groups: 1- HS (n = 61), 2- MSA patients (n = 19), and 3- PD patients (n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. RESULTS: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/− 7.62 ng/mL and 53.63 +/− 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%(P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = −0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. CONCLUSIONS: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics.
format Online
Article
Text
id pubmed-8477135
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-84771352021-10-04 Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients Ogura, Hiromu Hatip-Al-Khatib, Izzettin Suenaga, Midori Hatip, Funda Bolukbasi Mishima, Takayasu Fujioka, Shinsuke Ouma, Shinji Matsunaga, Yoichi Tsuboi, Yoshio eNeurologicalSci Original Article BACKGROUND AND PURPOSE: There is sufficient evidence to support vitamin D's noncalcemic effects and the role of vitamin D deficiency in the development of a wide range of neurological disorders. This study aimed to evaluate whether serum 25(OH)D and 1,25(OH) 2 D could be used as biomarkers to differentiate between healthy subjects (HS), multiple system atrophy (MSA) and Parkinson's disease (PD) patients of both genders. METHODS: A total of 107 subjects were included in this study, divided into three groups: 1- HS (n = 61), 2- MSA patients (n = 19), and 3- PD patients (n = 27). The patients were assessed using UMSARS II, UPDRS III, H&Y, MMSE and MoCA rating scales. The levels of 25(OH)D and 1,25(OH) 2 D in serum were determined using the radioimmunoassay technique. RESULTS: The levels of 25(OH)D and 1,25(OH) 2 D in HS were 26.85 +/− 7.62 ng/mL and 53.63 +/− 13.66 pg/mL respectively. 25(OH)D levels were lower in both MSA and PD by 61% and 50%, respectively (P = 0.0001 vs. HS). 1,25(OH) 2 D levels were lower in MSA by 29%(P = 0.001 vs HS). There was a correlation between 25(OH)D and 1,25(OH) 2 D in MSA and PD, but not in HS. 1,25(OH) 2 D regressed with MMSE (β = 0.476, P = 0.04, R 2 = 0.226) in MSA, and with UPDRS III (β = −0.432, P = 0.024, R 2 = 0.187) and MoCA (β = 0.582, P = 0.005,R 2 = 0.279) in PD. 25(OH)D displayed considerable differentiative strength between HS and MSA (Wald = 17.123, OR = 0.586, P = 0.0001; AUC = 0.982, sensitivity and Youden index = 0.882, P = 0.0001) and PD (Wald = 18.552, OR = 0.700, P = 0.0001; AUC = 0.943, sensitivity = 0.889, YI = 0.791, P = 0.0001). 1,25(OH) 2 D distinguished MSA from PD (Wald 16.178, OR = 1.117, P = 0.0001; AUC = 0.868, sensitivity = 0.926, Youden index =0.632, P = 0.0001). H&Y exhibited the highest sensitivity, AUC, and significant distinguishing power between MSA and PD. CONCLUSIONS: Serum 25(OH)D and 1,25(OH) 2 D could be useful biomarkers for MSA and PD. 25(OH)D and H&Y provided the highest sensitivity and group classification characteristics. Elsevier 2021-09-23 /pmc/articles/PMC8477135/ /pubmed/34611554 http://dx.doi.org/10.1016/j.ensci.2021.100369 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Ogura, Hiromu
Hatip-Al-Khatib, Izzettin
Suenaga, Midori
Hatip, Funda Bolukbasi
Mishima, Takayasu
Fujioka, Shinsuke
Ouma, Shinji
Matsunaga, Yoichi
Tsuboi, Yoshio
Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
title Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
title_full Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
title_fullStr Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
title_full_unstemmed Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
title_short Circulatory 25(OH)D and 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and Parkinson's disease patients
title_sort circulatory 25(oh)d and 1,25(oh)(2)d as differential biomarkers between multiple system atrophy and parkinson's disease patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8477135/
https://www.ncbi.nlm.nih.gov/pubmed/34611554
http://dx.doi.org/10.1016/j.ensci.2021.100369
work_keys_str_mv AT ogurahiromu circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT hatipalkhatibizzettin circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT suenagamidori circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT hatipfundabolukbasi circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT mishimatakayasu circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT fujiokashinsuke circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT oumashinji circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT matsunagayoichi circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients
AT tsuboiyoshio circulatory25ohdand125oh2dasdifferentialbiomarkersbetweenmultiplesystematrophyandparkinsonsdiseasepatients